Answers are grounded in this paper and cite their sources.
Case report reveals improvement in behavioral symptoms from subclinical seizures with levetiracetam, highlighting metabolic issues.
To describe a patient with ASXL3 mutation presenting with behavioral dysregulation and new-onset seizures, whose combativeness likely reflected subclinical seizures that improved with levetiracetam, and to discuss associated metabolic abnormalities.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: